Cardiome Pharma (CRME) Receives Daily Coverage Optimism Score of 0.17

Media coverage about Cardiome Pharma (NASDAQ:CRME) (TSE:COM) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cardiome Pharma earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 44.752789990176 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of Cardiome Pharma (CRME) traded up $0.01 on Friday, hitting $1.59. 69,273 shares of the stock were exchanged, compared to its average volume of 72,854. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.52 and a quick ratio of 4.71. The stock has a market cap of $55.41, a P/E ratio of -1.89 and a beta of 0.83. Cardiome Pharma has a 1-year low of $1.29 and a 1-year high of $4.84.

Cardiome Pharma (NASDAQ:CRME) (TSE:COM) last announced its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.04). The company had revenue of $6.02 million during the quarter, compared to analysts’ expectations of $7.42 million. Cardiome Pharma had a negative net margin of 112.91% and a negative return on equity of 94.68%. The business’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.19) EPS. equities analysts forecast that Cardiome Pharma will post -0.84 EPS for the current fiscal year.

Several analysts have recently commented on CRME shares. Zacks Investment Research upgraded shares of Cardiome Pharma from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research note on Wednesday, November 1st. HC Wainwright restated a “buy” rating and issued a $9.50 target price on shares of Cardiome Pharma in a research note on Wednesday, November 22nd. Canaccord Genuity set a $5.00 target price on shares of Cardiome Pharma and gave the stock a “buy” rating in a research note on Wednesday, November 15th. Finally, Mackie upgraded shares of Cardiome Pharma to a “buy” rating in a research note on Friday, December 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $5.50.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Week Herald and is owned by of Week Herald. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at

About Cardiome Pharma

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.

Insider Buying and Selling by Quarter for Cardiome Pharma (NASDAQ:CRME)

Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with's FREE daily email newsletter.

Leave a Reply